Discovery Laboratories, Inc. (NASDAQ:DSCO)
| CAPS Rating |
|
|---|---|
| Open | $2.64 |
| Previous Close | $2.67 |
| Daily Range | $2.60 - $2.75 |
| 52-Week Range | $1.44 - $3.03 |
| Market Cap | $64.22M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 210,615 |
| Average Daily Volume | 0 |
DSCO
VS S&P 500 (SPY)
How do you think DSCO will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
DSCO Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
DSCO News and Commentary
- Current M21 RL Positions: 2012 – Blog at The Motley Fool
- Project Mayhem Redux – Blog at The Motley Fool
- Current M21 RL Positions: June 2011 – Blog at The Motley Fool
- DSCO still on track to file in Q3 and hope for approval in Q1 2012 – Blog at The Motley Fool
- Current M21 RL Positions: April – Blog at The Motley Fool
- The Motley Fool's Weekly Editors' Picks – The Motley Fool
- Closing Bell: A Double From Lows (CAGC, CMCSA, DELL, DSCO, FDO, GENZ, SNY) – BloggingStocks
- DSCOD is delaying FDA attempt until fall. – Blog at The Motley Fool
- Discovery Labs Sees Filing Surfaxin Response With FDA In 3Q – SmartMoney
- Provectus Pharmaceuticals, Inc. (PVCT): Two Catalysts are Approaching – Blog at The Motley Fool
- Discovery labs – Blog at The Motley Fool
- A Penny stock to boom or bust – Blog at The Motley Fool
- GBMB update – Blog at The Motley Fool
- GBMB update – Blog at The Motley Fool
- GBMB update – Blog at The Motley Fool
- UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial – Reuters
- Discovery Labs: On Track To Complete FDA Response On Surfaxin – SmartMoney
- UPDATE 1-Discovery Labs completes quality test for lung drug – Reuters
- GBMB update – Blog at The Motley Fool
- Why I'm Down More than 85%, and How You Can Avoid My Mistakes – The Motley Fool
RSS Headlines
Fool UK
